Infectious diseases caused by viral or bacterial pathogens are a major cause of death and morbidity worldwide and constitute an ever growing medical need. We are focusing on discovery, research and development of new anti-infective agents, targeting both the pathogen as well as the host immune defences. In this, we build on an industry-leading technology platform and on a rich legacy of research in this field, which produced some outstanding therapeutics in hepatitis B, influenza and multi-drug resistant bacterial infections.
Dicerna – research collaboration and licensing agreement to develop siRNA therapies for the treatment of chronic hepatitis B virus (HBV) infection
Forge Therapeutics – Collaboration agreement to identify and develop a novel antibiotic for treating serious lung infections attributed to antibiotic-resistant Gram-negative bacteria./p>
VenatoRx – Collaboration agreement to develop a new class of intravenous antibiotics that overcomes existing antimicrobial resistance mechanisms.
Enza di Modugno, Head of Immunology, CVM & Infectious Diseases, Pharma Partnering
Jean-Eric Charoin, Search and Evaluation Lead Immunology, CVM and Infectious Diseases